<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="MEDLINE" Owner="NLM">
      <PMID Version="1">29210287</PMID>
      <DateCompleted>
        <Year>2018</Year>
        <Month>08</Month>
        <Day>17</Day>
      </DateCompleted>
      <DateRevised>
        <Year>2018</Year>
        <Month>11</Month>
        <Day>13</Day>
      </DateRevised>
      <Article PubModel="Print-Electronic">
        <Journal>
          <ISSN IssnType="Electronic">1473-2300</ISSN>
          <JournalIssue CitedMedium="Internet">
            <Volume>46</Volume>
            <Issue>2</Issue>
            <PubDate>
              <Year>2018</Year>
              <Month>Feb</Month>
            </PubDate>
          </JournalIssue>
          <Title>The Journal of international medical research</Title>
          <ISOAbbreviation>J Int Med Res</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Dexmedetomidine protects against oxygen-glucose deprivation/reoxygenation injury-induced apoptosis via the p38 MAPK/ERK signalling pathway.</ArticleTitle>
        <Pagination>
          <StartPage>675</StartPage>
          <EndPage>686</EndPage>
          <MedlinePgn>675-686</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1177/0300060517734460</ELocationID>
        <Abstract>
          <AbstractText>Objective To investigate the protective effects of dexmedetomidine (DEX) in oxygen-glucose deprivation/reoxygenation (OGD/R) injury, which is involved in a number of ischaemic diseases. Methods An in vitro OGD/R injury model was generated using mouse Neuro 2A neuroblastoma (N2A) cells. Different concentrations of DEX were administrated to OGD/R cells. CV-65 was used to inhibit p38 microtubule associated protein kinase/extracellular signal-regulated kinases (MAPK/ERK) signalling. Cell proliferation, cell cycle, apoptosis, and the levels of proteins related to p38 MAPK/ERK signalling and apoptosis were evaluated using Cell Counting Kit-8, flow cytometry, TdT-UTP nick end labelling and Western blot analysis, respectively. Results DEX treatment of OGD/R cells promoted cell survival and attenuated OGD/R-induced cell apoptosis. It also activated the p38 MAPK/ERK signalling pathway, increased the levels of Bcl-2, and decreased the levels of Bax and cleaved caspase-3. Treatment with the p38 MAPK/ERK inhibitor CV-65 inhibited the activation of p38 MAPK/ERK and abrogated the DEX-induced effects on cell survival and apoptosis. Conclusions DEX protects N2A cells from OGD/R-induced apoptosis via the activation of the p38 MAPK/ERK signalling pathway. DEX might be an effective agent for the treatment of ischaemic diseases.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Wang</LastName>
            <ForeName>Ke</ForeName>
            <Initials>K</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anaesthesiology, Suzhou Wuzhong People's Hospital, Suzhou, Jiangsu Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Zhu</LastName>
            <ForeName>Yuekun</ForeName>
            <Initials>Y</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Anaesthesiology, Suzhou Wuzhong People's Hospital, Suzhou, Jiangsu Province, China.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>06</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>J Int Med Res</MedlineTA>
        <NlmUniqueID>0346411</NlmUniqueID>
        <ISSNLinking>0300-0605</ISSNLinking>
      </MedlineJournalInfo>
      <ChemicalList>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D018712">Analgesics, Non-Narcotic</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C494827">Bax protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="C472784">CV 65 compound</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D020011">Protective Agents</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D019253">Proto-Oncogene Proteins c-bcl-2</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D015363">Quinolones</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>0</RegistryNumber>
          <NameOfSubstance UI="D051028">bcl-2-Associated X Protein</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>114100-40-2</RegistryNumber>
          <NameOfSubstance UI="C052617">Bcl2 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>67VB76HONO</RegistryNumber>
          <NameOfSubstance UI="D020927">Dexmedetomidine</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="C535148">Mapk1 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D019950">Mitogen-Activated Protein Kinase 1</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048052">Mitogen-Activated Protein Kinase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 2.7.11.24</RegistryNumber>
          <NameOfSubstance UI="D048051">p38 Mitogen-Activated Protein Kinases</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="C505409">Casp3 protein, mouse</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>EC 3.4.22.-</RegistryNumber>
          <NameOfSubstance UI="D053148">Caspase 3</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>IY9XDZ35W2</RegistryNumber>
          <NameOfSubstance UI="D005947">Glucose</NameOfSubstance>
        </Chemical>
        <Chemical>
          <RegistryNumber>S88TT14065</RegistryNumber>
          <NameOfSubstance UI="D010100">Oxygen</NameOfSubstance>
        </Chemical>
      </ChemicalList>
      <CitationSubset>IM</CitationSubset>
      <MeshHeadingList>
        <MeshHeading>
          <DescriptorName UI="D018712" MajorTopicYN="N">Analgesics, Non-Narcotic</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D017209" MajorTopicYN="N">Apoptosis</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D053148" MajorTopicYN="N">Caspase 3</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D002453" MajorTopicYN="N">Cell Cycle</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D045744" MajorTopicYN="N">Cell Line, Tumor</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D049109" MajorTopicYN="N">Cell Proliferation</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020927" MajorTopicYN="N">Dexmedetomidine</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015972" MajorTopicYN="Y">Gene Expression Regulation, Neoplastic</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D005947" MajorTopicYN="N">Glucose</DescriptorName>
          <QualifierName UI="Q000172" MajorTopicYN="N">deficiency</QualifierName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019950" MajorTopicYN="N">Mitogen-Activated Protein Kinase 1</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048052" MajorTopicYN="N">Mitogen-Activated Protein Kinase 3</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D009474" MajorTopicYN="N">Neurons</DescriptorName>
          <QualifierName UI="Q000187" MajorTopicYN="Y">drug effects</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
          <QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D010100" MajorTopicYN="N">Oxygen</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D020011" MajorTopicYN="N">Protective Agents</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="Y">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D019253" MajorTopicYN="N">Proto-Oncogene Proteins c-bcl-2</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015363" MajorTopicYN="N">Quinolones</DescriptorName>
          <QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D015398" MajorTopicYN="N">Signal Transduction</DescriptorName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D051028" MajorTopicYN="N">bcl-2-Associated X Protein</DescriptorName>
          <QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
        <MeshHeading>
          <DescriptorName UI="D048051" MajorTopicYN="N">p38 Mitogen-Activated Protein Kinases</DescriptorName>
          <QualifierName UI="Q000037" MajorTopicYN="N">antagonists &amp; inhibitors</QualifierName>
          <QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName>
          <QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName>
        </MeshHeading>
      </MeshHeadingList>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">Dexmedetomidine</Keyword>
        <Keyword MajorTopicYN="N">apoptosis</Keyword>
        <Keyword MajorTopicYN="N">oxygen-glucose deprivation/reoxygenation (OGD/R) injury</Keyword>
        <Keyword MajorTopicYN="N">p38 MAPK/ERK</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2018</Year>
          <Month>8</Month>
          <Day>18</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2017</Year>
          <Month>12</Month>
          <Day>7</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>ppublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">29210287</ArticleId>
        <ArticleId IdType="pmc">PMC5971521</ArticleId>
        <ArticleId IdType="doi">10.1177/0300060517734460</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>Nie H, Xue X, Liu Get al.
Nitro-oleic acid ameliorates
oxygen and glucose deprivation/re-oxygenation triggered oxidative stress in
renal tubular cells via activation of Nrf2 and suppression of NADPH
oxidase.
Free Radic Res
2016; 50:
1200–1213.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27545328</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>He K, Yan L, Pan CSet al.
ROCK-dependent ATP5D
modulation contributes to the protection of notoginsenoside NR1 against
ischemia-reperfusion-induced myocardial injury.
Am J Physiol Heart Circ Physiol
2014; 307:
H1764–H1776.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25305180</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wei S, Tong J, Xue Qet al.
Effect of puerarin on
transcriptome of astrocyte during oxygen-glucose deprivation/reoxygenation
injury.
Mol Cell Biochem
2017; 425:
113–123.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27844252</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Page A, Lane A, Taylor Ret al.
Trends in socioeconomic
inequalities in mortality from ischaemic heart disease and stroke in
Australia, 1979–2006.
Eur J Prev Cardiol
2012; 19:
1281–1289.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22007040</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pasin L, Greco T, Feltracco Pet al.
Dexmedetomidine as a
sedative agent in critically ill patients: a meta-analysis of randomized
controlled trials.
PLoS One
2013; 8: e82913.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3877008</ArticleId>
            <ArticleId IdType="pubmed">24391726</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Feng JF, Wang XX, Lu YYet al.
Effects of dexmedetomidine
versus midazolam for premedication in paediatric anaesthesia with
sevoflurane: A meta-analysis.
J Int Med Res
2017; 45:
912–923.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5536403</ArticleId>
            <ArticleId IdType="pubmed">28425829</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim WH, Cho D, Lee Bet al.
Changes in brain activation
during sedation induced by dexmedetomidine.
J Int Med Res
2017; 45:
1158–1167.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5536405</ArticleId>
            <ArticleId IdType="pubmed">28480811</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Maier C, Steinberg GK, Sun GHet al.
Neuroprotection by the
α2-Adrenoreceptor agonist dexmedetomidine in a focal model of cerebral
ischemia.
Anesthesiology
1993; 79:
306–312.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">8102042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kuhmonen J, Pokorny J, Miettinen Ret al.
Neuroprotective effects of
dexmedetomidine in the gerbil hippocampus after transient global
ischemia.
Anesthesiology
1997; 87:
371–377.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">9286902</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hoffman WE, Kochs E, Werner Cet al.
Dexmedetomidine improves
neurologic outcome from incomplete ischemia in the rat. Reversal by the
alpha 2-adrenergic antagonist atipamezole.
Anesthesiology
1991; 75:
328–332.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">1677549</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Eser O, Fidan H, Sahin Oet al.
The influence of
dexmedetomidine on ischemic rat hippocampus.
Brain Res
2008; 1218:
250–256.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">18514174</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Ren X Ma H andZuo Z.. 
Dexmedetomidine postconditioning reduces brain injury after brain
hypoxia-ischemia in neonatal rats.
J Neuroimmune Pharmacol
2016; 11:
238–247.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26932203</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim E, Kim H, Lee Set al.
Dexmedetomidine confers
neuroprotection against transient global cerebral ischemia/reperfusion
injury in rats by inhibiting inflammation through inactivation of the
TLR-4/NF-κB pathway.
Neurosci Lett
2017; 649:
20–27.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28392361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Hu Z, Yang B, Mo Xet al.
HspB8 mediates
neuroprotection against OGD/R in N2A cells through the phosphoinositide
3-kinase/Akt pathway.
Brain Res
2016; 1644:
15–21.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27178361</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Pipaón C, Gutierrez P, Montero JCet al.
Mitogen-activated protein
kinase routes as targets in the action of diaza-anthracene compounds with a
potent growth-inhibitory effect on cancer cells. Mol
Cancer Ther
2002; 1:
811–819.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12492114</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Mao Y, Wu S, Zhao Ret al.
MiR-205 promotes
proliferation, migration and invasion of nasopharyngeal carcinoma cells by
activation of AKT signalling.
J Int Med Res
2016; 44:
231–240.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5580060</ArticleId>
            <ArticleId IdType="pubmed">26880795</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu D, Lu P, Zhang Ket al.
EGFR mediates astragaloside
IV-induced Nrf2 activation to protect cortical neurons against in vitro
ischemia/reperfusion damages.
Biochem Biophys Res Commun
2015; 457:
391–397.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">25582778</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang Q, Wu D, Yang Yet al.
Effects of dexmedetomidine
on the protection of hyperoxia-induced lung injury in newborn
rats.
Int J Clin Exp Pathol
2015; 8:
6466–6473.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4525857</ArticleId>
            <ArticleId IdType="pubmed">26261523</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen JH, Yu GF, Jin SYet al.
Activation of α2 adrenoceptor attenuates
lipopolysaccharide-induced hepatic injury. Int J
Clin Exp Pathol
2015; 8:
10752–10759.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4637601</ArticleId>
            <ArticleId IdType="pubmed">26617786</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Gu J, Sun P, Zhao Het al.
Dexmedetomidine provides
renoprotection against ischemia-reperfusion injury in mice.
Crit Care
2011; 15: R153.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3219027</ArticleId>
            <ArticleId IdType="pubmed">21702944</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zeng X, Wang H, Xing Xet al.
Dexmedetomidine protects
against transient global cerebral ischemia/reperfusion induced oxidative
stress and inflammation in diabetic rats.
PLoS One
2016; 11:
e0151620.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4794239</ArticleId>
            <ArticleId IdType="pubmed">26982373</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Jiang L, Li L, Shen Jet al.
Effect of dexmedetomidine on
lung ischemia-reperfusion injury.
Mol Med Rep
2014; 9:
419–426.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3896524</ArticleId>
            <ArticleId IdType="pubmed">24345905</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang JJ, Peng K, Zhang Jet al.
Dexmedetomidine
preconditioning may attenuate myocardial ischemia/reperfusion injury by
down-regulating the HMGB1-TLR4-MyD88-NF-кB signaling
pathway.
PLoS One
2017; 12:
e0172006.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5319750</ArticleId>
            <ArticleId IdType="pubmed">28222157</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Wang Y, Chen G, Yu Xet al.
Salvianolic acid B
ameliorates cerebral ischemia/reperfusion injury through inhibiting
TLR4/MyD88 signaling pathway.
Inflammation
2016; 39:
1503–1513.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">27255374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Liu R, Zhang L, Lan Xet al.
Protection by borneol on
cortical neurons against oxygen-glucose deprivation/reperfusion: involvement
of anti-oxidation and anti-inflammation through nuclear transcription factor
κB signaling pathway.
Neuroscience
2011; 176:
408–419.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21168474</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Chen Z Qiu PY andMa CG.. 
Dexmedetomidine preconditioning protects against retinal
ischemia/reperfusion injury and inhibits inflammation response via toll-like
receptor 4 (TLR4) pathway.
Biomed Pharmacother
2017; 93:
1018–1024.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28724211</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Zhang F, Ding T, Yu Let al.
Dexmedetomidine protects
against oxygen-glucose deprivation-induced injury through the I2 imidazoline
receptor-PI3K/AKT pathway in rat C6 glioma cells.
J Pharm Pharmacol
2012; 64:
120–127.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22150679</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Luo C, Ouyang MW, Fang YYet al.
Dexmedetomidine protects
mouse brain from ischemia-reperfusion injury via inhibiting neuronal
autophagy through up-regulating HIF-1α.
Front Cell Neurosci
2017; 11: 197.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC5498477</ArticleId>
            <ArticleId IdType="pubmed">28729825</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Si Y, Bao H, Han Let al.
Dexmedetomidine protects
against renal ischemia and reperfusion injury by inhibiting the JAK/STAT
signaling activation.
J Transl Med
2013; 11: 141.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3700850</ArticleId>
            <ArticleId IdType="pubmed">23759023</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Sun Y, Liu WZ, Liu Tet al.
Signaling pathway of
MAPK/ERK in cell proliferation, differentiation, migration, senescence and
apoptosis.
J Recept Signal Transduct Res
2015; 35:
600–604.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26096166</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Johnson GL andLapadat R.. 
Mitogen-activated protein kinase pathways mediated by ERK, JNK,
and p38 protein kinases.
Science
2002; 298:
1911–1912.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12471242</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Kim EK andChoi EJ.. 
Pathological roles of MAPK signaling pathways in human
diseases.
Biochim Biophys Acta
2010; 1802:
396–405.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20079433</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>Furler RL andUittenbogaart CH.. 
Signaling through the P38 and ERK pathways: a common link between
HIV replication and the immune response.
Immunol Res
2010; 48:
99–109.</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">20725863</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
